9th Circ. Won't Rethink FCA Disclosure Ruling Against Valeant
A Ninth Circuit panel on Friday denied drugmaker Valeant Pharmaceuticals' request to review its decision to revive a False Claims Act suit accusing Valeant of fraudulently obtaining a patent to extend...To view the full article, register now.
Already a subscriber? Click here to view full article